Literature DB >> 24790479

Acute impact of inhaled short acting b2-agonists on 5 km running performance.

John Dickinson1, Jiu Hu2, Neil Chester2, Mike Loosemore3, Greg Whyte2.   

Abstract

Whilst there appears to be no ergogenic effect from inhaled salbutamol no study has investigated the impact of the acute inhalation of 1600 µg, the World Anti-Doping Agency (WADA) daily upper limit, on endurance running performance. To investigate the ergogenic effect of an acute inhalation of short acting β2-agonists at doses up to 1600 µg on 5 km time trial performance and resultant urine concentration. Seven male non-asthmatic runners (mean ± SD; age 22.4 ± 4.3 years; height 1.80 ± 0.07 m; body mass 76.6 ± 8.6 kg) provided written informed consent. Participants completed six 5 km time-trials on separate days (three at 18 °C and three at 30 °C). Fifteen minutes prior to the initiation of each 5 km time-trial participants inhaled: placebo (PLA), 800 µg salbutamol (SAL800) or 1600 µg salbutamol (SAL1600). During each 5 km time-trial HR, VO2, VCO2, VE, RPE and blood lactate were measured. Urine samples (90 ml) were collected between 30-180 minutes post 5 km time-trial and analysed for salbutamol concentration. There was no significant difference in total 5 km time between treatments (PLA 1714.7 ± 186.2 s; SAL800 1683.3 ± 179.7 s; SAL1600 1683.6 ± 190.7 s). Post 5 km time-trial salbutamol urine concentration between SAL800 (122.96 ± 69.22 ug·ml(-1)) and SAL1600 (574.06 ± 448.17 ug·ml(-1)) were not significantly different. There was no improvement in 5 km time-trial performance following the inhalation of up to 1600 µg of salbutamol in non-asthmatic athletes. This would suggest that the current WADA guidelines, which allow athletes to inhale up to 1600 µg per day, is sufficient to avoid pharmaceutical induced performance enhancement. Key pointsInhaling up to 1600 µg of Salbutamol does not result in improved 5 km time trial performance.The position of Salbutamol on the World Anti-Doping Agency list of prohibited appears justified.Athletes who use up to 1600 µg Salbutamol in one day need to review their therapy as it would suggest their respiratory condition is not under control.

Entities:  

Keywords:  Anti-Doping; WADA code; asthma; athlete care; treatment

Year:  2014        PMID: 24790479      PMCID: PMC3990879     

Source DB:  PubMed          Journal:  J Sports Sci Med        ISSN: 1303-2968            Impact factor:   2.988


  20 in total

1.  Standardisation of spirometry.

Authors:  M R Miller; J Hankinson; V Brusasco; F Burgos; R Casaburi; A Coates; R Crapo; P Enright; C P M van der Grinten; P Gustafsson; R Jensen; D C Johnson; N MacIntyre; R McKay; D Navajas; O F Pedersen; R Pellegrino; G Viegi; J Wanger
Journal:  Eur Respir J       Date:  2005-08       Impact factor: 16.671

2.  Treatment of airway inflammation improves exercise pulmonary gas exchange and performance in asthmatic subjects.

Authors:  Hans C Haverkamp; Jerome A Dempsey; David F Pegelow; Jordan D Miller; Lee M Romer; Marcus Santana; Marlowe W Eldridge
Journal:  J Allergy Clin Immunol       Date:  2007-04-23       Impact factor: 10.793

3.  Impact of changes in the IOC-MC asthma criteria: a British perspective.

Authors:  J W Dickinson; G P Whyte; A K McConnell; M G Harries
Journal:  Thorax       Date:  2005-08       Impact factor: 9.139

4.  Urine concentrations of repetitive doses of inhaled salbutamol.

Authors:  J Elers; L Pedersen; J Henninge; P Hemmersbach; K Dalhoff; V Backer
Journal:  Int J Sports Med       Date:  2011-05-11       Impact factor: 3.118

5.  Impact of changes in anti-doping regulations (WADA Guidelines) on asthma care in athletes.

Authors:  Mariana Couto; Luís Horta; Luís Delgado; Miguel Capão-Filipe; André Moreira
Journal:  Clin J Sport Med       Date:  2013-01       Impact factor: 3.638

6.  Effects of short-term oral salbutamol administration on exercise endurance and metabolism.

Authors:  K Collomp; R Candau; F Lasne; Z Labsy; C Préfaut; J De Ceaurriz
Journal:  J Appl Physiol (1985)       Date:  2000-08

Review 7.  Asthma and the elite athlete: summary of the International Olympic Committee's consensus conference, Lausanne, Switzerland, January 22-24, 2008.

Authors:  Kenneth D Fitch; Malcolm Sue-Chu; Sandra D Anderson; Louis-Philippe Boulet; Robert J Hancox; Donald C McKenzie; Vibeke Backer; Kenneth W Rundell; Juan M Alonso; Pascale Kippelen; Joseph M Cummiskey; Alain Garnier; Arne Ljungqvist
Journal:  J Allergy Clin Immunol       Date:  2008-08       Impact factor: 10.793

8.  Effects of acute salbutamol inhalation on quadriceps force and fatigability.

Authors:  Nicolas Decorte; Samuel Verges; Patrice Flore; Michel Guinot; Bernard Wuyam
Journal:  Med Sci Sports Exerc       Date:  2008-07       Impact factor: 5.411

9.  Field exercise vs laboratory eucapnic voluntary hyperventilation to identify airway hyperresponsiveness in elite cold weather athletes.

Authors:  Kenneth W Rundell; Sandra D Anderson; Barry A Spiering; Daniel A Judelson
Journal:  Chest       Date:  2004-03       Impact factor: 9.410

10.  Inhaled salbutamol does not affect athletic performance in asthmatic and non-asthmatic cyclists.

Authors:  Sarah Koch; Martin J MacInnis; Benjamin C Sporer; James L Rupert; Michael S Koehle
Journal:  Br J Sports Med       Date:  2013-10-07       Impact factor: 13.800

View more
  4 in total

Review 1.  The impact of exercise-induced bronchoconstriction on athletic performance: a systematic review.

Authors:  Oliver J Price; James H Hull; Vibeke Backer; Morten Hostrup; Les Ansley
Journal:  Sports Med       Date:  2014-12       Impact factor: 11.136

2.  Self-Administration of Medicines and Dietary Supplements Among Female Amateur Runners: A Cross-Sectional Analysis.

Authors:  Médéa Locquet; Charlotte Beaudart; Robert Larbuisson; Victoria Leclercq; Fanny Buckinx; Jean-François Kaux; Jean-Yves Reginster; Olivier Bruyère
Journal:  Adv Ther       Date:  2016-10-31       Impact factor: 3.845

3.  Exercise performance after salbutamol inhalation in non-asthmatic, non-athlete individuals: a randomised, controlled, cross-over trial.

Authors:  Filip Eckerström; Christian Emil Rex; Marie Maagaard; Sune Rubak; Vibeke Elisabeth Hjortdal; Johan Heiberg
Journal:  BMJ Open Sport Exerc Med       Date:  2018-08-30

4.  Model-based meta-analysis of salbutamol pharmacokinetics and practical implications for doping control.

Authors:  Perrine Courlet; Thierry Buclin; Jérôme Biollaz; Irene Mazzoni; Olivier Rabin; Monia Guidi
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2022-03-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.